Partners Welcome

CharlestonPharma is focused on developing innovative therapeutic antibodies to nucleolin and related diagnostic tests for cancer patients and healthcare providers.

Our strategy is to develop in vivo proof of efficacy and selected safety data for our antibodies and seek one or more partners for clinical development and commercialization of our therapeutic antibodies and diagnostic tests.

CharlestonPharma's intellectual property includes patents licensed on a worldwide basis from the Medical University of South Carolina covering the composition of fully human antibodies to nucleolin and from the University of Louisville which claim the use and composition of antibodies to nucleolin to treat cancer patients as well as use of cell surface nucleolin in the prognosis and diagnosis of cancer.

Interested parties may contact us at